Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-51. (Canceled)

52. (Currently amended) A method of treating a human subject suffering loss of photoreceptor function and autosomal dominant retinitis pigmentosa due to expression of a mutant human opsin protein with a substitution of Proline 23 by Histidine (P23H mutant opsin protein), said method comprising:

treating loss of photoreceptor function in the human subject by administering to the subject an effective amount of a synthetic retinoid that is <u>9-cis-12-methyl retinal</u> a derivative of 9 cis retinal, wherein said derivative is capable of inducing the *in vivo* folding and stabilization of a P23H mutant opsin protein to form visual pigment after intraocular injection into an eye of a transgenic mouse expressing the human P23H mutant opsin protein,

wherein the human subject has autosomal dominant retinitis pigmentosa due to expression of the P23H mutant opsin protein.

- 53. (Canceled)
- 54. (Previously presented) The method of claim 52, wherein the synthetic retinoid is in a pharmaceutically acceptable vehicle.
- 55. (Previously presented) The method of claim 52, wherein the synthetic retinoid is orally administered to the human subject.
- 56. (Previously presented) The method of claim 52, wherein the synthetic retinoid is locally administered to the human subject.

- 57. (Previously presented) The method of claim 56, wherein the synthetic retinoid is locally administered by eye drops.
- 58. (Previously presented) The method of claim 56, wherein the synthetic retinoid is locally administered by intraocular injection.
- 59. (Previously presented) The method of claim 56, wherein the synthetic retinoid is locally administered by periocular injection.
- 60. (Previously presented) The method of claim 52, wherein the subject endogenously forms rhodopsin, from opsin and endogenous 11-cis-retinal, as a visual pigment.
- 61. (Currently amended) [[he] <u>The</u> method of claim 56, wherein the subject endogenously forms rhodopsin, from opsin and endogenous 11-cis-retinal, as a visual pigment.
- 62. (Previously presented) The method of claim 52, further comprising identifying the subject as expressing a P23H mutant opsin protein before said administering.
 - 63-71. (Canceled).